Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion cash, in a deal designed to expand the buyer’s cancer pipeline with Halda’s precision oncology candidates, led by a ...

Starting in 2026, NIBRT training will be piloted at Heartland BioWorks’ Indianapolis headquarters with hands-on training beginning in 2027.

A molecular switch in breast cancer cells reprograms the genetic production line towards tumor growth and stress resistance.

Tumors trigger T-cell exhaustion through a TSP-1–CD47 signaling pathway. Blocking it can restore immune strength and improve cancer treatment.

AAV-SLB101 is a rationally designed capsid developed for enhanced skeletal muscle, cardiac tropism, and reduced biodistribution to the liver.

The Fugaku supercomputer builds a highly detailed virtual mouse cortex with millions of neurons enabling unprecedented ...

Korro Bio saw its stock reach all-time lows on disappointing data for its lead pipeline candidate, while Intellia Therapeutics saw analyst downgrades on safety concerns despite releasing positive data ...

Merck & Co. has agreed to acquire Cidara Therapeutics for approximately $9.2 billion, the companies said, in a deal designed to bolster the buyer’s antiviral portfolio with a Phase III drug designed ...

Prophylactic HPV vaccines prevent infection but not existing disease. A nasal nanogel vaccine shows preclinical promise for ...

The data, which is being presented at this year's AMP meeting, offers some insights into the often hidden causes of recurrent pregnancy loss.

Animal testing is costly, slow, and poorly predictive. ORIVA offers a human-relevant alternative with the potential to change that.

Microrobots could be precisely directed, under clinical conditions, by integrating systems for navigation, therapeutic ...